Although we clearly demonstrate that the 3E8-mEndo fusion protein has improved anti-angiogenic activities, an extended half-life in circulation, higher localization in the tumor mass, and significantly enhanced anti-tumor activities compared endostatin, the following issues must be considered before clinical application of this fusion protein in anti-cancer therapeutics. Here, COL18A1 is linked to neoplasm.